Canopy Growth Corporation (CGC) has a MoatMap StockRank of 30/100 based on Quality (33/100), Value (52/100), and Momentum (33/100) factor scores. The current signal is SELL. Canopy Growth operates in the nascent and highly regulated cannabis industry, which typically involves significant R&D, uncertain profitability, and is far from an asset-light, high ROIC quality compounder. It's often viewed as a turnaround story, which is explicitly avoided by the Terry Smith lens. No clear macro tailwind for an asymmetric opportunity.
Canopy Growth Corporation is a global leader in the cannabis and hemp-derived products market, involved in cultivation, processing, and sales of a wide range of medical and recreational cannabis products. The company leverages its extensive brand portfolio, significant cultivation infrastructure, and strategic partnerships, including with Constellation Brands, to maintain a prominent market position. As an early mover in regulated cannabis markets, it has established a broad consumer reach and continues to invest in product innovation and market expansion.
| Price | $1.04 |
| Market Cap | $496M |
| P/E (Forward) | -15.33 |
| Price/Book | 0.74 |
| Return on Equity | -48.5% |
| Return on Invested Capital | -63.5% |
| Debt/Equity | 33.65 |
| Gross Margin | 26.6% |
| Operating Margin | -17.6% |
| Revenue Growth | -0.3% |
| Free Cash Flow | $-26M |
Canopy Growth Corporation operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Canada).